Sugi Predict

Sugi Predict / Compounds / SCHEMBL319769

SCHEMBL319769

SCHEMBL319769

COc1ccc(CNc2ncc(F)cn2)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 1/20 0.58
▸ HDAC3 O15379 1/20 0.57
▸ HDAC1 Q13547 1/20 0.57
▸ HDAC2 Q92769 1/20 0.57
▸ HDAC6 Q9UBN7 1/20 0.57
▸ CYP1A2 P05177 12/20 0.52
▸ CYP3A4 P08684 12/20 0.52
▸ CYP2D6 P10635 12/20 0.52
▸ CYP2C19 P33261 11/20 0.52
▸ TSHR P16473 10/20 0.52
▸ ALDH1A1 P00352 4/20 0.52
▸ CYP2C9 P11712 4/20 0.52
▸ USP2 O75604 4/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ LMNA P02545 4/20 0.51
▸ HIF1A Q16665 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ CLK4 Q9HAZ1 6/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29669029 0.85 CYP1A2 (0.58) APLNRHDAC3HDAC1HDAC2HDAC6
SCHEMBL322187 0.85 CYP1A2 (0.58) APLNRHDAC3HDAC1HDAC2HDAC6
SCHEMBL319266 0.84 APLNR (0.63) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL15400259 0.79 APLNR (0.61) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20238025 0.79 APLNR (0.52) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL24963702 0.77 CYP1A2 (0.56) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL29377730 0.77 CYP1A2 (0.58) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL22497892 0.77 CYP1A2 (0.58) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL21551236 0.77 CYP1A2 (0.52) APLNRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL23694524 0.77 CYP1A2 (0.52) APLNRCYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2022-04-12 — — US disclosed
CN-108349963-B Sodium channel blockers 株式会社大熊制药 2021-03-30 — — CN disclosed
CN-109526219-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2021-03-12 — — CN disclosed
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 — — US disclosed
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 — — US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 — — US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 — — US disclosed
EP-3375782-B1 SODIUM CHANNEL BLOCKER DAE WOONG PHARMA (KR) 2020-07-29 — — EP disclosed
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-05-26 — — US disclosed
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-05-26 — — US disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 — — EP disclosed
WO-2014170792-A1 SULFONAMIDE DERIVATIVES AS URAT-1 INHIBITORS PFIZER LIMITED (GB) 2014-10-23 — — WO disclosed
US-20140315878-A1 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2014-10-23 — — US disclosed
US-20140296245-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS, INC. (CA) 2014-10-02 — — US disclosed
EP-2590972-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 — — EP disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 — — US disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B APLNR 3569/4885HDAC3 518/4885HDAC1 1420/4885
US-20140296245-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS TRPV1, TRPA1, TRPV3 APLNR 3528/4885HDAC3 564/4885HDAC1 1815/4885
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B APLNR 3569/4885HDAC3 518/4885HDAC1 1420/4885
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B APLNR 3439/4885HDAC3 585/4885HDAC1 1621/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B APLNR 3569/4885HDAC3 518/4885HDAC1 1420/4885
US-20140315878-A1 CHEMICAL COMPOUNDS SULT2A1, SULT1A1, SULT1E1 APLNR 2292/4885HDAC3 466/4885HDAC1 298/4885
US-20130109667-A1 Chemical Compounds SCN1A, SCN7A, SCN1B APLNR 2091/4885HDAC3 681/4885HDAC1 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.